Top

News & Events

Archive: 2018

News Archive

Genesis 2018

13 December 2018
Genesis 2018
London, UK

Read more »

Scrip Awards 2018

28 November 2018
Scrip Awards 2018
London, UK

Read more »

14th Annual BioProcessUK Conference 2018

20 - 22 November 2018
14th Annual BioProcessUK Conference 2018
Edinburgh, UK

Read more »

One Nucleus BioWednesday - Stevenage

14 November 2018
One Nucleus BioWednesday - Stevenage
Stevenage, UK

Read more »

Jefferies 2018 London Healthcare Conference

14 - 15 November
Jefferies 2018 London Healthcare Conference
London, UK

Read more »

The Lifestars Awards

13 November 2018
The Lifestars Awards
London, UK

Read more »

Biotech and Money 3rd annual Inv€$tival Showcase in partnership with Jefferies

13 November 2018
Biotech and Money 3rd annual Inv€$tival Showcase in partnership with Jefferies
London, UK

Read more »

Bio-Europe 2018

5-7 November 2018
Bio-Europe 2018
Copenhagen, Denmark

 

Read more »

AusBiotech 2018

31 October - 2 November 2018
AusBiotech 2018
Brisbane, Australia 

Read more »

BIA UK Bioscience Forum 2018

18 October 2018
BIA UK Bioscience Forum 2018
London, UK

Read more »

OBN Awards 2018

11 October 2018
OBN Awards 2018
Oxford, UK

Read more »

Sachs 6th Annual Medtech & Digital Health Forum

05 October 2018
Sachs 6th Annual Medtech & Digital Health Forum
Basel, Switzerland

Read more »

Sachs 18th Annual Biotech in Europe Forum

04 - 05 October 2018
Sachs 18th Annual Biotech in Europe Forum
Basel, Switzerland
 

Read more »

OBN BioForward 2018

04 October 2018
OBN BioForward 2018
Birmingham, UK

Read more »

Joint BIA and Harwell Campus Networking Lunch

3 October 2018
Joint BIA and Harwell Campus Networking Lunch
Oxford, UK

Read more »

BIA Biotech IPOs: what are we AIMing for?

28 September 2018
BIA Biotech IPOs: what are we AIMing for?
London, UK

Read more »

One Nucleus BioWednesday London September

26 September 2018
One Nucleus BioWednesday London September
London, UK

Read more »

BIA Meet the Chinese Investors

26 September 2018
BIA Meet the Chinese Investors
Instinctif Partners Office 

Read more »

BIA Women in Biotech Networking Evening - September

19 September 2018
BIA Women in Biotech Networking Evening - September
London, UK

Read more »

BIA Developing, feeding and restoring the human microbiome

13 September 2018
BIA Developing, feeding and restoring the human microbiome
Webinar

Read more »

One Nucleus BioWednesday Cambridge September 2018

12 September 2018
One Nucleus BioWednesday Cambridge September 2018
Cambridge, UK

Read more »

BIA Networking Lunch - Stevenage

6 September 2018
BIA Networking Lunch - Stevenage
Stevenage, UK

Read more »

Annual Edison Summer Party

06 September 2018
Annual Edison Summer Party
London, UK

Read more »

Biotech Buddies

3 September 2018
Biotech Buddies
London, UK 

Read more »

Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers

LONDON, BOSTON, TOKYO – The first half of 2018 has seen biopharma IPOs and venture financing accelerate from the already-healthy levels witnessed in 2017. Deal making has dimmed further, however, raising concern that overheated valuations in certain pockets of the sector are putting off buyers.

Read more »

Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine®Platform in Patients with Advanced Solid Cancers

Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA202, its second T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA202 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors. The single-center clinical study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Read more »

SkinBioTherapeutics plc Business update

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health,  is pleased to provide the following update:

Read more »

One Nucleus Summer Social 2018

15 August 2018
One Nucleus Summer Social 2018
Cambridge, UK

 

Read more »

DNAe Chosen as Best Diagnostic Medtech Company Finalist in the 2018 OBN Awards

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted as a finalist for the 2018 OBN Awards, in the category ‘Best Diagnostic Medtech Company’. These prestigious industry award nominations recognise and celebrate leading companies in the Life Sciences industry.

Read more »

Feedback plc: First GE Healthcare order for TexRAD® medical imaging software

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received its first order via GE Healthcare (GEHC) for TexRAD®, its patented image texture analysis technology.

Read more »

Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of targeted T-cell engagers, today announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE:4502).

Read more »

Instinctif Partners Congratulates the Shortlisted Nominees for the 2018 OBN Awards

London, UK - Instinctif Partners, the international business communications consultancy, congratulates the nominees shortlisted as finalists for the 2018 OBN Awards. Now in its 10th anniversary, the OBN Awards are one of the most prestigious and competitive awards events in the UK life sciences industry, this year receiving a 40% increase in award entries compared to 2017.

Read more »

BioWednesday London: Media Question Time

8 August 2018
BioWednesday London: Media Question Time 2018
London, UK

 

Read more »

DNAe Named as Top Innovator Finalist in the Inaugural 2018 Medtech Insight Awards

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted for the inaugural 2018 Medtech Insight Awards, in the category ‘Most Innovative Team or Innovator of the Year’.

Read more »

Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena

Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic antibody, Clevegen®, being developed by clinical stage biotechnology company, Faron Pharmaceuticals.

Read more »

Cell Medica Appoints New CEO to Drive CAR and TCR Clinical Development and Commercialisation

LONDON and HOUSTON – Cell Medica (or ‘the Company’), a leader in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director. His appointment follows founder Gregg Sando’s decision to step down as Chief Executive Officer and Director of the Company and is effective 1 August 2018.

Read more »

Key Australian Patent for Recce’s Broad-Spectrum Antibiotics

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX:RCE) (Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced that Australian patent WO2016/077879 ‘Copolymer and Method for Treatment of Bacterial Infection’, has been accepted for grant by the Australian Patent Office. The patent is the first of Recce’s patent family 2 (Multi Drug Applications) and offers significant additional market monopolies to November 2034.

Read more »

MerLion Regains North American Rights to XTORO™ FDA-Approved Antibiotic for Treatment of Ear Infections

Singapore - MerLion Pharmaceuticals (MerLion), a pharmaceutical company, focused on the advanced clinical development of its antibacterial drug finafloxacin, today announced that Novartis has made a portfolio decision and terminated the license between Alcon (a subsidiary of Novartis) and MerLion executed in 2010 and returned all rights to MerLion. MerLion now owns all rights to XTORO™ globally.

Read more »

Abzena signs protein engineering agreement with NYU Langone Health

Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug discovery services, will help NYU Langone’s drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics.

Read more »

Healx Raises $10m as Investors Back AI to Find Rare Disease Treatments Faster

Cambridge, UK – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced a $10 million Series A funding round led by Balderton Capital, Europe's leading early-stage venture investor. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.

Read more »

Forbion Portfolio Company Replimune Successfully Completes IPO on NASDAQ

Naarden, The Netherlands, and Munich – Forbion, a leading European life science venture capital firm, today announces that its portfolio company Replimune Group, Inc. (‘Replimune’) has successful completed an initial public offering (IPO) on NASDAQ, raising over $100 million for the development of its next-generation oncolytic immunotherapies. Replimune’s stock has started trading under the ticker symbol “REPL”.

Read more »

Mobile Responsive Technology Powers Biotech-Pharma Business Growth through an Enhanced partneringONE® Conference Software Experience

Carlsbad, CA – EBD Group (‘EBD’), the market leading provider of world-class partnering events and tools for the global life science industry, has released a significant update of its gold-standard partnering software, partneringONE®, based on a fully responsive mobile platform.

Read more »

Clinigen acquires global rights to Imukin® from Horizon Pharma

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has acquired the global rights to Imukin® (recombinant human interferon gamma-1b) from Horizon Pharma plc (‘Horizon’). Horizon will retain the rights to Actimmune® (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Read more »

F-star Announces the Achievement of a Clinical Milestone in its Immuno-Oncology Collaboration with Merck

Cambridge, UK, – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies (mAb²™), today announces that FS118 has successfully reached the first clinical milestone in its collaboration with Merck, a leading science and technology company.

Read more »

SkinBioTherapeutics receives provisional ethics approval for human study

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life sciences company focused on skin health, announces that it has received provisional ethics approval for its human study scheduled to start later this year.

Read more »

Clinigen acquires global rights to Proleukin® outside the United States

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has acquired the global rights to Proleukin® (aldesleukin, recombinant interleukin-2) outside the United States from Novartis. Financial details have not been disclosed.

Read more »

Update on Progress of Broad Spectrum Antibiotic RECCE®327 Towards Clinical Trials

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX:RCE) (Company), the Company developing a new class of synthetic, broad spectrum antibiotics, today provided an update on its progress towards the start of human trials of its lead compound RECCE®327, for the treatment of sepsis, including a simple clinical trial design.

Read more »

Clinigen Year end trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the year ended 30 June 2018.

Read more »

BIA Summer Networking Reception 2018

12 July 2018
BIA Summer Networking Reception 2018
London, UK

Read more »

BIA Parliament Day

12 July 2018
BIA Parliament Day
London, UK

Read more »

Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies

Tuebingen, Germany – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today that it has entered into a research collaboration and license agreement with Genmab A/S (Nasdaq Copenhagen: GEN) to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.

Read more »

Forbion exceeds target with EUR 270 million first close of its fourth life sciences VC fund

Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, has today announced the first close of its fourth flagship fund Forbion IV, at EUR 270 million, exceeding the EUR 250 million target size.

Read more »

On Helix 2018

10-11 July 2018
On Helix 2018
Cambridge, UK

Read more »

OBN Summer Drinks 2018

3 July 2018
OBN Summer Drinks
Oxford, UK

Read more »

Abzena and Telix sign strategic manufacturing and bioconjugation agreement

Cambridge, UK and Melbourne, Australia – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are expected to be substantially completed within a 15 month period.

Read more »

Crescendo Biologics Appoints Clinical Development Expert, Dr Igor Matushansky, as Non-Executive Director

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Igor Matushansky, MD, PhD, has been appointed as Non-Executive Director of the Company with immediate effect.

Read more »

Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research

Cambridge, UK, - Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.

Read more »

BioWednesday Cambridge: From the Golden Gate to the Golden Triangle 2018

27 June 2018
BioWednesday Cambridge: From the Golden Gate to the Golden Triangle
Cambridge, UK

Read more »

LSX Connect: Summer 2018

27 June 2018
LSX Connect: Summer
​London, UK

Read more »

Reapplix: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions and Business Update

Birkerød, Denmark – Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.

Read more »

Neural Analytics, Inc. Receives CE Mark for its Robotic Ultrasound System

Los Angeles, CA,USA – Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announced today that it received CE Mark for its NeuralBot™ System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. When used with its previously cleared Lucid™ M1 Transcranial Doppler Ultrasound System®, it can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders.

Read more »

National Care Group marks major expansion in the West Midlands with acquisition of Shelton Care

Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Shelton Care in Stoke-on-Trent. Financial details of the deal were not disclosed.

Read more »

Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.

Read more »

Crescendo Biologics Appoints Eva-Lotta Allan as Non-Executive Director

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Eva-Lotta Allan has been appointed as Non-Executive Director of the Company with immediate effect.

Read more »

European Mediscience Awards 2018

14 June 2018
European Mediscience Awards 2018
London, UK

Read more »

BIA Women in Biotech Networking Evening - June

14 June 2018
BIA Women in Biotech Networking Evening - June
London, UK

Read more »

Clinigen signs exclusive supply & distribution agreement with Lukare for Elliotts B® Solution

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Lukare Medical (‘Lukare’) to manage the supply and distribution of Elliotts B® Solution.

Read more »

Dirk Kersten joins Forbion as General Partner

Naarden, The Netherlands – Forbion, one of the leading European life science venture capital firms, today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.

Read more »

Cell Medica Appoints Julia P. Gregory as Non-Executive Director and Audit Chair

Houston and London – Cell Medica (or ‘the Company’), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.

Read more »

Xellia Pharmaceuticals Appoints Matthew Anderson as Chief Financial Officer

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, announced today that it has further strengthened its leadership team by appointing Matthew Anderson as Chief Financial Officer (CFO) with immediate effect. He will be taking over from the current interim CFO, Otto Rasmussen.

Read more »

Bumper biodollar deals for biotech clients

Congratulations to our clients Fstar, Hookipa and Microbiotica, each pioneering disruptive technologies for the development of tomorrow’s therapeutics. They have announced bio-dollar deals collectively worth up to ~$1.4 billion.

Read more »

Instinctif Partners’ Life Sciences Clients Have Bumper Week of Deal Making, Announcing Deals of ~$1.4 Billion

London, UK: The life sciences team at International business communications consultancy Instinstif Partners is pleased to have supported three clients that are pioneering disruptive technologies to develop tomorrow’s therapeutics in their announcements around big bio-dollar deals worth some $1.4 billion.

Read more »

Worldwide Prescription Drug Sales Accelerate to $1.2 Trillion by 2024, as Unmet Need Drives Annual Compound Growth to Over 6%

London, Boston, Tokyo — Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market according to Evaluate’s annual industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024”. The rare disease space is predicted to capture 20% of the total $1.2trn market in 2024. Supporting this growth are the launches of novel therapies, including gene and cell therapies, as well as increased access to medicines globally.

Read more »

Microbiotica Enters into Microbiome Collaboration with Genentech

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).

Read more »

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

Vienna, Austria and Foster City, CA - Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, today announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Read more »

Recce Pharmaceuticals: Update on meeting with US FDA

Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today said it had received formal guidance following its meeting last month with the US Food & Drug Administration’s Division of Anti-Infective Products, Office of Antimicrobial Products.

Read more »

BIO International Convention 2018

4-7 June 2018
BIO International Convention 2018
Boston, USA

Read more »

Future Oncology publishes dexrazoxane article supporting EC removal of restrictions for use in children and adolescents

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, notes the publication in Future Oncology of a peer reviewed article by expert physicians evaluating recent research and publications on dexrazoxane, marketed by Clinigen as Cardioxane®. The physicians concluded that dexrazoxane’s cardioprotectant benefits outweighed the risks for its use in children and adolescent cancer patients, which is consistent with the EC’s change of label approval in 2017.

Read more »

Full year results: a year of transition - revenue growth driven by investment programme

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2018.

Read more »

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has signed a commercial agreement with Bristol-Myers Squibb (‘BMS’) in South Africa. The agreement covers BMS’ South African portfolio of products for an initial period of five years.

Read more »

F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma

Cambridge, UK – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, announced today that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to acquire the asset-centric vehicle F-star Gamma Ltd (F-star Gamma).

Read more »

Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications

Shanghai, and Cambridge, UK — Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Crescendo Biologics Ltd (Crescendo Biologics), the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialize, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications. 

Read more »

Worldwide Orphan Drug Sales are Forecast to Grow at a CAGR of 11.3% from 2018 to 2024, Double the Rate Forecast for the Non-Orphan Drug Market

London, UK, Boston, US and Tokyo, JapanContinuing unmet medical need is set to fuel the growth of the worldwide orphan drug market, with sales predicted to grow at over 11% a year to $262bn by 2024, according to EvaluatePharma’s fifth Orphan Drug Report.

Read more »

SkinBioTherapeutics to fulfil industrial partner role in skin health research grant awarded to the University of Manchester

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the ‘Company’), a life science company focused on skin health, announces its collaboration as industrial partner in a grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester (the ‘University’).

Read more »

Clinigen signs agreement with Nordic Pharma for aprotinin

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the supply and distribution of aprotinin in a range of countries in Asia Pacific and South Africa.

Read more »

Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.

Read more »

Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint® and BluePrint® to Patients in Southeast Asia

Irvine, CA and Amsterdam, Netherlands– Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint® Breast Cancer Risk of Recurrence test and the BluePrint® Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.

Read more »

Biotech Investment Showcase 2018

22 - 23 May 2018
Biotech Investment Showcase 2018
London, UK

 

Read more »

BIA UK CEO and Investor Forum 2018

23-24 May 2018
BIA UK CEO and Investor Forum 2018
Buckinghamshire, UK

Read more »

OBN BioTuesday- Medtech Showcase 2018

22 May 2018
OBN BioTuesday- Medtech Showcase 2018
Manchester, UK

Read more »

Labiotech Refresh 2018

22 May 2018
Labiotech Refresh 2018
Brussels, Belgium

Read more »

Microbiotica to Present at Top Microbiome Conferences

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June.

Read more »

Clinigen and Mitsubishi Tanabe initiate European Managed Access Program for edaravone to treat ALS

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

Read more »

F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-class Immuno-oncology Bispecific Antibody

Cambridge, UK – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, today announced successful dosing of the first patient with FS118 in a Phase I clinical trial.

Read more »

Seventure Partners Life Sciences Corporate Update January - April 2018

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for the period January-April 2018.

Read more »

New Insights into Hookipa’s TheraT® Replicating Viral Vector Platform published in Immunity

Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases, today announces the publication of a new preclinical study of its TheraT® replicating viral platform in the May edition of the prestigious international peer-reviewed journal Immunity1.

Read more »

Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer Centers (FCCC).

Read more »

Immatics Appoints Stephen Eck as Chief Medical Officer US

Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. (Houston, Texas), effective immediately.

Read more »

Bio€quity Europe 2018

14-16 May 2018
Bio€quity Europe 2018
Ghent, Belgium

Read more »

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio

TÜBINGEN, Germany — Acousia Therapeutics (Acousia), a leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, today announced the closing of a €10 million Series B financing round to advance its pipeline of preclinical drug candidates into clinical stage.

Read more »

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

Read more »

Astex’s Harren Jhoti made Fellow of the Royal Society

Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.

Read more »

BIA Annual Lecture - An evening with Sir David Cooksey GBE

03 May 2018
BIA Annual Lecture - An evening with Sir David Cooksey GBE
London, UK

Read more »

BIA - Financing opportunities from China: targeting investors and shaping deals

2 May 2018
BIA - Financing opportunities from China: targeting investors and shaping deals
London, UK

Read more »

SkinBioTherapeutics finalises plans for human study of cosmetic application and progresses manufacturing scale-up

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health,  is pleased to provide the following update:

Read more »

Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing

Cambridge, UK — Crescendo Biologics Ltd (Crescendo) the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced today that it has completed a $70 million (€57 million) Series B financing.

Read more »

Belgian Microbiome Spin-off A-Mansia Announces €13m First Close of Series A Financing

Louvain-la-Neuve, Belgium – A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, led by Seventure Partners. The financing round remains open for additional investment.

Read more »

Rapid Detection of Pathogen and Antibiotic Resistance with DNAe’s LiDia® Bloodstream Infection (BSI) Technology

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, announces new data generated with its LiDia® Bloodstream Infection (BSI) technology, currently in development. The LiDia® BSI method was demonstrated to detect pathogen and antibiotic resistance in samples collected from patients after receiving antibiotic therapy. Time to detection by the LiDia® BSI method was significantly shorter (hours vs. days) compared to standard-of-care blood culture testing.

Read more »

Recce Pharmaceuticals: Pharmaceutical Expert Joins Board of Directors

Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today announced the appointment of Dr John Prendergast to its Board as an independent Non-Executive Director.

Read more »

BioScience Managers: Downing FOUR VCT invests £1.14 million in ADC Biotechnology Ltd

London, UK – London-based investment management firm, Downing LLP, and BioScience Managers Limited, the international healthcare investment firm and advisers to the Downing FOUR VCT, today announce the completion of a new £1.14 million investment in Wales-based ADC Biotechnology Ltd.

Read more »

Biotrinity 2018

23-25 April 2018
Biotrinity
London, UK

Read more »

Additional AU$861,590 R&D Tax Incentive Rebate for RECCE® 327 Antibiotic

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today confirmed it has received an additional $861,590 from the Australian Government for its overseas Advanced Drug Development expenditure in FY2017 under the Australian Government’s Research and Development (R&D) Tax Incentive program.

Read more »

Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization in Preparation for the Launch of its Value-Added Anti-Infective Drug Products

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announced today that it has appointed Craig Boyd to the new leadership role of President, Xellia US. Craig will be responsible for leading the growth of Xellia’s US business as the Company prepares to launch its pipeline of value-added anti-infective drug products into the US market. Xellia is also significantly expanding its commercial organization with a new office planned in Chicago to complement its increased US manufacturing capabilities as its facilities in Cleveland Ohio come into full operation in 2018.

Read more »

SkinBioTherapeutics’ technology, SkinBiotix®, shows positive results in cream formulation

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces that the ‘cream’ formulation of its SkinBiotix® technology has passed effectiveness studies in models of skin. The cream formulation will now undergo further testing for stability in the coming weeks.

Read more »

Crescendo Biologics Reaches First Major Milestone in Strategic Collaboration with Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of multifunctional biologics, including targeted T-cell engagers, today announced that it has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502).

Read more »

DNAe to Present New Data and Preview its Blood-to-Result Test for Bloodstream Infection at ECCMID 2018

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections that can lead to sepsis, announces that new data will be presented on its LiDia® Bloodstream Infection (BSI) test1,2 at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Madrid, Spain, 21-24th April, 2018.

Read more »

PTX-200 Phase 1b Breast Cancer Trial Results Prescient’s Most Significant Clinical Milestone to Date

Melbourne, Australia - Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is delighted to announce that the patients evaluable for efficacy in the PTX-200 Phase 1b breast cancer trial exhibited an overall response rate of 50%, against an expected industry average response rate of 25% with paclitaxel alone.  In patients with locally advanced disease, two patients had pathologic complete responses (40%), meaning a complete eradication of cancer.

Read more »

Forbion participates in £29M Series B Financing of Enterprise Therapeutics to Advance its Ion Channel Modulators for the treatment of Cystic-fibrosis, COPD and severe asthma

Naarden, The Netherlands – Forbion, one of the leading European life science venture capital firms, today announces that it participated together with new investors Versant Ventures and Novartis Venture Fund and existing investors Epidarex Capital and IP Group in an oversubscribed £29M investment round in the UK biotech company Enterprise Therapeutics. The investment will fund the Company’s drug discovery pipeline of muco-regulatory therapies into clinical development, enabling new treatment options for cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma.

Read more »

MerLion Pharmaceuticals: Positive Phase II Data of Finafloxacin Antibiotic Published in Three Papers in Antimicrobial Agents and Chemotherapy

Singapore - MerLion Pharmaceuticals (MerLion) today announced that three papers summarizing clinical data from its Phase II clinical trial with finafloxacin in complicated urinary tract infections (cUTIs) have been published online in the peer-reviewed journal Antimicrobial Agents and Chemotherapy and in the print version of the April issue. Finafloxacin is a novel antibiotic that, as well as an outstanding safety profile, demonstrates strong antibacterial activity under acidic conditions; differentiating it from other existing antibiotic therapies and offering new, exciting treatment opportunities.

Read more »

NorthSea Therapeutics: Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

Naarden, The Netherlands – NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company aiming to develop novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, announces the publication of a late-breaker abstract and poster to be presented at The EASL International Liver CongressTM 2018 in Paris on 12-14 April.

Read more »

One Health Tech - Digitising ‘Old School’ Healthcare Practice

10 April 2018
One Health Tech - Digitising ‘Old School’ Healthcare Practice
London, UK

Read more »

F-star to Present New Preclinical Data on FS118, a First-in-Class Immuno-Oncology Bispecific Antibody, at the AACR 2018 Annual Meeting

Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces that new preclinical data from its lead immuno-oncology programme FS118 will be highlighted at the American Association of Cancer Research (AACR) Annual Meeting in Chicago, US from 14 – 18 April 2018.

Read more »

SkinBioTherapeutics signs Material Transfer Agreement with global consumer goods company

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces the signing of a Material Transfer Agreement (MTA) relating to its proprietary SkinBiotix® technology with a major, global consumer goods company.

Read more »

Sir David King Joins Emergex’s Board of Directors

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.

Read more »

April Funding Update

Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today advises that in view of the Company’s current liquidity and the imminent receipt of a further AU$853,000 from the Federal Government under its R&D rebate scheme, the Board believes the Company has sufficient funds to meet its near-term objectives as it continues to maintain a prudent and cautious approach to managing its finances. Thus, it has decided to exercise its right to defer the next AU$50,000 equity investment from the Australian Special Opportunity Fund managed by The Lind Partners under its AU$6.05 million funding agreement executed in 2017.

Read more »

Emergex builds its Finance Team with Two New Recruits

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.

Read more »

Hookipa Biotech to Present New Phase 1 Data for its Cytomegalovirus Vaccine, HB-101 at the World Vaccine Congress

Vienna, Austria – Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases, will present new data from a Phase 1 trial of HB-101, a vaccine against human cytomegalovirus (CMV).

Read more »

CMO Appointment and Clinical Trials Update

Melbourne, Australia – Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company, today announced the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO) and provides an update on the development plan for its lead therapeutic program, DMX-200 for Chronic Kidney Disease (CKD).

Read more »

e-therapeutics - Full Year Results

Oxford, UK - e-therapeutics plc (AIM: ETX, “e-therapeutics” or the “Company”), the drug discovery company, announces its full year results for the year ended 31 January 2018.

Read more »

Emergex Progresses its Synthetic Vaccine Development Pipeline

Oxford, UK – Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.

Read more »

Facility remodelling completed for Abzena’s new antibody-drug conjugate GMP manufacturing suite

Cambridge, UK and Bristol PA, USA - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site.

Read more »

The Future of Swedish & Danish Life Science 2018

22-23 March 2018
The Future of Swedish & Danish Life Science 2018
Lund, Sweden 

Read more »

BIA Networking Breakfast

BIA Networking Breakfast
22 March 2018
Cambridge, UK

Read more »

Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company owned by Novo Holdings A/S, today reported its financial results for the year ending December 31, 2017 and provided an update on its product portfolio. Xellia is focused on providing important anti-infective treatments against serious and often life-threatening infections.

Read more »

Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.

Read more »

Crescendo Biologics Appoints Dani Bach as Non-Executive Director

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Dani Bach has been appointed as Non-Executive Director of the Company with immediate effect. Dani replaces Rob Woodman as the representative for IP Group plc., now one of the largest shareholders of the Company.

Read more »

Adisseo and Seventure Partners Announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the innovative venture capital fund, targeted at supporting companies in the field of animal health, feed and nutrition. The first close of AVF at €24m, is corner stoned by Adisseo, an industry leader in the animal feed sector.

Read more »

OBN BioTuesday 2018

20 March 2018

OBN BioTuesday 2018

Cambridge, UK

Read more »

Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos® (CPX-351) outside the United States

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been appointed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ, ‘Jazz’) to distribute Vyxeos® (daunorubicin and cytarabine) liposome for injection via a Managed Access Program (‘MAP') outside the United States.

Read more »

Medicxi unveils ‘The Foundation Institute’

London & Geneva & Jersey – Medicxi, the leading European life sciences investment firm, today announces a new initiative named ‘The Foundation Institute for 21st Century Medicine’ based in Cambridge, U.K. (‘The Foundation Institute’ or ‘C21Med’).

Read more »

Digitising ‘Old School’ Healthcare Practice

Digitising ‘Old School’ Healthcare Practice

10 April 2018

Instinctif Partners London, UK

Read more »

Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)

Naarden, The Netherlands – Forbion, one of the leading European life science venture capital firms, today announces that H. Lundbeck A/S (Lundbeck) has acquired Forbion’s portfolio company Prexton Therapeutics B.V. (Prexton) for a total consideration of EUR 905 million (USD 1.1 billion).

Read more »

ON Career Track 2018

16 March 2018
ON Career Track
London, UK

Read more »

Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

Cambridge, UK – Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

Read more »

Guide to Best Practice Communications for R&D Based Biotechs Webinar

Listen to managing partner Sue Charles chair the BIA webinar on the principles and application of the Guide to Best Practice Communications for R&D based biotechs.

Read more »

Wired Health 2018

14 March 2018
Wired Health 2018
London, UK

Read more »

8th Annual Advanced Therapies Summit

8th Annual Advanced Therapies Summit
14 March 2018
Amsterdam, Netherlands

Read more »

Forbion leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

Naarden, The Netherlands – 13 March 2018 – Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical RORγt drug candidates for psoriasis and other autoimmune diseases.

Read more »

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository.

Read more »

Women in Biotech Networking Evening 2018

8 March 2018
Women in Biotech Networking Evening 2018
London, UK

Read more »

Meeting with US FDA on Phase I Clinical Trial for RECCE® 327 Antibiotic

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it has been invited to attend a face-to-face meeting with the US Food and Drug Administration (FDA) to discuss its unique technology and proposed clinical and regulatory pathway for its lead synthetic antibiotic compound RECCE® 327.

Read more »

FDA Grants Breakthrough Device Designation to Polyganics’ Liver and Pancreas Sealant Patch

Groningen, The Netherlands – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch. The Liver and Pancreas Sealant patch is considered a unique breakthrough in the prevention of fluid leakage after hepato-pancreato-biliary (HPB) procedures, for which currently no approved or cleared alternatives exist.

Read more »

Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.

Read more »

The PR industry and General Data Protection Regulation (GDPR) 2018

07 March 2018
The PR industry and General Data Protection Regulation (GDPR) 2018
London, UK

Read more »

Clinigen strengthens senior management team in Clinical Trial Services and Commercial Medicines

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Terry Walsh as Senior Vice President of Clinical Trials Services (‘CTS’). Clinigen has also promoted Benjamin Miny, the former Managing Director of Clinigen South Africa, to Senior Vice President of Commercial Medicines.

Read more »

The Impact of MiFID II on the UK Biotech Industry

MiFID II. An acronym that instils a broad set of emotions across the City of London, ranging from blind panic in some quarters to mild indifference in others. This widely quoted but little understood abbreviation of the second Markets in Financial Instruments Directive is already having an effect across the industry. However, the fact that each financial institution is interpreting the regulations in different ways show the level of confusion, with some continuing as if nothing has changed, whilst others feel that sending a piece of research to a PR is an invitation to buy or sell shares.

Read more »

Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development

Cambridge, UK – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.

Read more »

Evaluate Ltd: Fast Pace of Drug and Device Approvals in 2017 Signals Wider Sector Health for Biopharma but Medtech Companies Struggle

LONDON, BOSTON, SAN FRANCISCO, TOKYO – Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for smaller groups. In biopharma, drug approvals in the US jumped, the IPO window was thrown open and venture funding soared. However, concerns about the growth prospects of large drug developers led to a disappointing year for some big pharma groups. In the device sector M&A activity increased markedly and all the big players saw their share prices head skywards. However, it was a dismal story on the funding and IPO front, continuing a trend that has lasted for several years.

Read more »

Congenica Achieves Global ISO 13485:2016 in vitro Diagnostic Device Quality Management Systems Certification

Cambridge, UK – Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.

Read more »

Clinigen: Good H1 performance with adjusted EPS up 13%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2017.

Read more »

Sachs 11th Annual European Life Sciences CEO Forum & Exhibition 2018

26-27 February 2018
11th Annual European Life Sciences CEO Forum & Exhibition 2018
Zurich, Switzerland

Read more »

Instinctif Partners collaborates with Kemivärlden Biotech med Kemisk Tidskrift for the 6th ‘Future of Swedish and Danish Life Science’ Event

London, UK: The Life Sciences practice of Instinctif Partners, the international business communications consultancy, entered into a sponsorship and support agreement as the official media partner for The Future of Swedish & Danish Life Science “The latest in Precision Medicine and Big Data” event.

Read more »

SkinBioTherapeutics plc: Half year results

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2017.

Read more »

Dimerix Raises a Further AU $4.5m Through Oversubscribed Placement

MELBOURNE, Australia – Dimerix Limited or the “Company” (ASX: DXB), a clinical-stage biotechnology company developing new therapeutic treatments using its proprietary assay technology has raised an additional AU $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint Lead managers to the Issue.

Read more »

Clinigen and Santhera launch US Expanded Access Program with Idebenone for patients with Duchenne Muscular Dystrophy

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has initiated an Expanded Access Program (‘EAP’) in the US with Santhera Pharmaceuticals (SIX: SANN, ‘Santhera’) for idebenone in patients with Duchenne Muscular Dystrophy (‘DMD’) who are in respiratory decline.

Read more »

Kevin S. Boyle, Sr. Appointed CFO to Lead Cell Medica Financing for Innovative CAR and TCR Cell Therapies

Houston and London - Cell Medica, a leader in cellular immunotherapy for the treatment of cancer, announced today the appointment of Kevin S. Boyle, Sr. as Chief Financial Officer, based in Houston, TX. With over 20 years of financial and capital markets experience, Kevin joins the senior executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilizing Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.

Read more »

Data Submission & Further Communication Request with US FDA

Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it has submitted additional data to the US Food and Drug Administration (FDA), including an additional communication request.

Read more »

Auspherix Awarded Innovate UK Grant to Test its Organogold Antibiotics to Treat Life-threatening Respiratory Infections

Stevenage, UK – Funding from Innovate UK, the UK’s Innovation agency, is enabling UK anti-infectives company Auspherix to expand into new therapeutic indications and test the activity of its new class of organogold antibacterial compounds against bacteria that cause respiratory infections including life-threatening lung infections such as hospital-acquired bacterial pneumonia (HABP). As the second most common hospital acquired infection, HABP is the primary cause of death in intensive care units with a mortality rate of ~30%.

Read more »

Congenica and SFI Research Centre FutureNeuro Unite to Deliver More Accurate Diagnoses for Genetic Epilepsy

Cambridge, United Kingdom and Dublin, Ireland – New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland. The software will be designed to work with electronic health record (EHR) systems, including the Irish electronic health record for Epilepsy, so that the entire diagnostic process, from initial DNA sequencing to determining treatment options, is available to clinicians and patients through their electronic records.

Read more »

Biotech and Money Reports 20% of investors shift focus to life science investment opportunities outside of the UK due to Brexit

London, UK - One-fifth (20%) of respondents to the 2nd Biotech and Money Investor Perception Survey report an increased focus on life science investment opportunities outside of the UK as a result of the UK’s decision to leave the EU. Although 38% of respondents are not currently seeing Brexit impact their investment strategy and believe that this will continue to be the case, a further 38% of respondents do expect Brexit to affect their investment strategy in the future.

Read more »

UK IPO Bootcamp

7 February 2018
UK IPO Bootcamp
London, UK

Read more »

New CatchPoint® SimpleStep® ELISA Fluorescent 90-Minute Assay

Cambridge, UK – CatchPoint® SimpleStep® ELISA (SSE) kits provide a simple and fast protocol with a single-wash step, assay time of 90 minutes or less, and a fluorometric readout that delivers an extended dynamic range.

Read more »

Hookipa Biotech to Attend the LEERINK Partners 7th Annual Global Healthcare Conference

Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that CEO Joern Aldag and CMO Igor Matushansky will be attending the LEERINK Partners 7th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, USA on Wednesday, February 14th and Thursday, February 15th, 2018.

Read more »

Introducing FirePlex®-HT High-Throughput Multiplex Immunoassays – Delivering More Data from Precious Samples

Cambridge, UK – FirePlex®-HT Immunoassays offer a no-wash workflow in 384-well plate format, enabling multiplex quantification of up to 10 protein analytes per well from as little as 6.25 ul of plasma, serum, or cell culture supernatant. A 2-step protocol limits hands-on time and can be easily automated, making the assay well-suited to high-throughput studies.

Read more »

Biotech and Money / Medtech and Money World Congress

5-6 February 2018

Biotech and Money / Medtech and Money World Congress

London, UK

Read more »

Abcam and Molecular Devices Announce Strategic Collaboration

Cambridge, UK and San Jose, CA, USA – Abcam, a global innovator in life science reagents and tools, and Molecular Devices, LLC, a leading provider of high-performance bioanalytical measurement solutions for the life science industry, today announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.

Read more »

Congenica Signs Strategic Digital Health Contracts During Official UK-China Trade Mission

Cambridge, UK – Today Congenica, the global provider of clinical genomics interpretation software, signed a series of significant memorandums of understanding (MOUs) with leading Chinese companies and healthcare providers at a UK-Chinese Future of Medicine trade event in Beijing, China. The meeting was held in conjunction with the State visit of Prime Minister May.

Read more »

Dimerix Limited Quarterly Review - Q2 FY2018

MELBOURNE, Australia - Dimerix Limited (ASX: DXB) (Dimerix or the Company), a clinical stage biotechnology company is pleased to release its Appendix 4C Quarterly Report for the three-month period ending 31 December 2017, together with a review of activities and developments from the quarter.

Read more »

Harren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association

Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been honoured with a Lifetime Achievement Award from the UK BioIndustry Association (BIA).

Read more »

Biotech and the City

25 January 2018
Biotech and the City
London, UK

Read more »

BIA Gala Dinner 2018

25 January 2018
BIA Gala Dinner 2018
London, UK

Read more »

Instinctif Partners welcomes the BIA’s Pipeline Progressing: The UK’s Global Bioscience Cluster in 2017

London, UK: The life sciences team of international business communications consultancy Instinctif Partners welcomes the launch of the UK BioIndustry Association’s (BIA) report on the progression of the UK’s bioscience industry during 2017

Read more »

Synthon’s [vic-]trastuzumab duocarmazine (SYD985) granted FDA Fast Track designation for pre-treated HER2-positive metastatic breast cancer

Nijmegen, the Netherlands  ̶  Synthon Biopharmaceuticals (‘Synthon’) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its investigational anti-HER2 antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985). This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease, or progressed during or after [ado-]trastuzumab emtansine treatment.

Read more »

Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business

Cambridge, United Kingdom  – Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer, David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors.

Read more »

Atomo Diagnostics and Access Bio partner to expand access to best-in-class HIV rapid testing in global markets

Sydney, Australia and Seoul, South Korea - Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets.

Read more »

Seventure Joins $35m Series B Round in Digital Nutrition Platform Zipongo

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces that it has joined a Series B funding round into Zipongo, investing $9m.

Read more »

Abcam Signs Exclusive License Agreement with Roche

Cambridge, UK – Abcam plc ("Abcam"), a global leader in the supply of life science research tools, is pleased to announce that it has entered into a definitive license agreement with Roche. Under the terms of the agreement Abcam will obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation (“Spring”) in the research use only (RUO) field of use, comprising a total of approximately 760 unique products (the “Spring Portfolio”). Roche, which acquired Spring in 2007, will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.

Read more »

Biotech and Money presents Biotech and Money/Medtech and Money World Congress on 5-6 February 2018

London, UK On 5-6 February, over 500 leading lights, emerging stars, C-suite executives, impactful investors and powerful stakeholders will attend the 4th annual Biotech and Money/Medtech and Money World Congress. The congress is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science companies need to enable more effective investment, business planning, and partnering within their businesses.

Read more »

OBN BioThirstday

18 January 2018
OBN BioThirstday
London, UK

Read more »

FuturaGene’s Exclusive License For RNAi Technology In Eucalyptus Enhanced By Grant Of Patent In Brazil

Canberra, Australia and Sao Paulo, Brazil – FuturaGene, a wholly owned subsidiary of Suzano Pulp and Paper, and Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO), are pleased to announce that a patent has been issued in Brazil to CSIRO, which covers the downregulation of the expression of plant target genes or other target genes, including genes of insect pests and disease agents. In 2014, FuturaGene entered into an exclusive license agreement with CSIRO for the use of RNAi technology in eucalyptus in Brazil. Under the license, FuturaGene has the right to sublicense the technology and has non-exclusive rights to the technology in eucalyptus outside of Brazil.  FuturaGene has been utilizing the technology to develop varieties of eucalyptus, which are resistant to pests and diseases and for modifying wood properties.

Read more »

Immatics Appoints Thomas Ulmer as Chief Financial Officer

Tuebingen, Germany and Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Thomas Ulmer as Chief Financial Officer (CFO), effective April 1, 2018.

Read more »

Clinigen Group plc: HY trading update: good H1 performance with profits up over 10%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2017.

Read more »

e-Therapeutics to collaborate with Intellegens and Biorelate to enhance and extend its AI technology capabilities

Oxford, UK - e-Therapeutics, a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, today announces agreements with Intellegens and Biorelate. Both companies have artificial intelligence (AI) tools which, after pilot studies, have been proven to enhance ETX’s existing computational NDD technology. No financial details were disclosed.

Read more »

AusIndustry Awards Recce Support for AU$5.6m of Technically Advanced Overseas Drug Development

SYDNEY Australia – Recce Pharmaceuticals Ltd (ASX: RCE), developing a new class of synthetic antibiotics, today announced that it has been awarded an Advanced Finding upon AU$5.6 million of overseas drug development from AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.

Read more »

Seventure Partners Life Sciences Investing Update - H2 2017

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for July – December 2017.

Read more »

One Nucleus Pub Social

10 January 2018
One Nucleus Pub Social
London, UK

Read more »

The UK BIA has launched a Best Practice Guide for Communicating R&D Progress to Investors and the Public

We welcome the launch of a new BioIndustry Association (BIA) guide to help bioscience companies communicate their R&D clearly and effectively to investors and the public.

Drawing on our decades or experience of advising public and private biotech companies in the UK and globally, Instinctif Partners supported the development of the guide, which can be downloaded HERE.

Read our INSIGHT on the importance of best practice communications in the biotech sector HERE.

Read more »

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK – Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.

Read more »

Instinctif Partners Welcomes the Publication of the new BIA Best Practice Guide for Communicating R&D Progress to Investors and the Public

London, UK - The life sciences team at International business communications consultancy Instinctif Partners welcomes the launch of a new guide to help bioscience companies communicate their R&D clearly and effectively to investors and the public.

Read more »

Clinigen extends agreement with Eisai to supply Halaven®, Fycompa® and Lenvima® into 10 African countries

Clinigen Group plc (AIM: CLIN, ‘Clinigen’) - Clinigen Group plc, the global pharmaceutical and services company, has extended its exclusive agreement with Eisai Europe Ltd to obtain the marketing authorisation and subsequently launch Halaven® (eribulin), Fycompa® (perampanel) and Lenvima® (lenvatinib) into 10 African countries.

Read more »